# **BC Cancer Protocol Summary for DOXOrubicin for Use in Patients with Advanced Soft Tissue Sarcoma**

Protocol Code SAAVA

**Tumour Group** Sarcoma

Contact Physician

Dr. Christine Simmons

#### **ELIGIBILITY:**

- Patients with an advanced soft tissue sarcoma
- Good performance status
- Adequate bone marrow, renal and hepatic function (bilirubin less than 2 x ULN)

#### **EXCLUSION:**

Rhabdomyosarcoma in young adults

#### TESTS:

- Baseline and before each treatment: CBC & diff, platelets, creatinine, bilirubin, ALT, alk phos, GGT, LDH and clinical measure of tumour response
- Every second treatment: chest x-ray or other imaging to monitor response

#### PREMEDICATIONS:

 Antiemetic protocol for High/Moderate emetogenic chemotherapy (see protocol SCNAUSEA)

## TREATMENT:

Drug	Dose	BC Cancer Administration Guidelines
DOXOrubicin	75 mg/m <sup>2</sup>	IV push

- For patients greater than 65 years old, consider reducing dose to 60 mg/m<sup>2</sup>
- Repeat every 21 days x 6 cycles

## **DOSE MODIFICATIONS:**

1. Hematological:

ANC (x 10 <sup>9</sup> /L)		Platelets (x 10 <sup>9</sup> /L)	Dose
greater than equal to 1.5	and	greater than equal to 100	100 %
1.0 to less than 1.5	or	70 to less than 100	80 %
less than 1.0	or	less than 70	Delay one week

- 2. **Mucositis:** Grade 3 or 4, reduce dose to 80%
- 3. Nausea & Vomiting: Grade 4 despite optimal use of antiemetics, reduce dose to 80% or QUIT
- 4. **Neutropenic Fever** (with ANC less than 0.5 x 10<sup>9</sup>/L): Once counts have recovered, reduce dose to 80%
- 5. **Hepatic Dysfunction:** For bilirubin 1.5 to 2 times ULN, reduce dose to 50%

#### PRECAUTIONS:

- Cardiac Toxicity: DOXOrubicin is cardiotoxic and must be used with caution in patients with severe hypertension or cardiac dysfunction. Cardiac assessment is recommended if lifelong dose of 450 mg/m<sup>2</sup> is exceeded (see BC Cancer Drug Manual).
- 2. **Extravasation:** DOXOrubicin causes pain and tissue necrosis if extravasated. Refer to BC Cancer Extravasation Guidelines.
- 3. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.

Call Dr. Christine Simmons or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.